Home › Compare › IQGLF vs ABBV
IQGLF yields 33.33% · ABBV yields 3.09%● Live data
📍 IQGLF pulled ahead of the other in Year 1
Combined, IQGLF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of IQGLF + ABBV for your $10,000?
IQGeo Group plc develops geospatial software to the telecoms and utility network industries in the United Kingdom, Europe, the United States, Canada, Japan, and internationally. The company provides IQGeo Platform, which designs and manages complex and constantly evolving network assets; IQGeo Network Manager that plans, designs, and supports network lifecycle through construction and maintenance operations; IQGeo Workflow Manager software, which helps to control telecom and utility construction and maintenance activities; IQGeo Inspection and Survey software that provides a flexible mobile interface for field inspection teams; and IQGeo Network Revenue Optimizer software, which automatically produces multiple telecom construction route options for connecting commercial or residential premises. It also offers IQGeo development environment to implement applications that work in any modern web browser and on any mobile device, online or offline; IQGeo Fiber Planning software, which automatically generates a cost-optimized next-generation fiber network plan and design; IQGeo in the cloud, a cloud hosting of critical system infrastructure; IQGeo GIS integrations for data integration from virtually any application and geospatial data source; and IQGeo professional services. The company was formerly known as Ubisense Group Plc and changed its name to IQGeo Group plc in January 2019. IQGeo Group plc was founded in 2002 and is headquartered in Cambridge, the United Kingdom.
Full IQGLF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.